Michael Elliott Bigby, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sentinel Lymph Node Biopsy | 8 | 2019 | 732 | 2.240 |
Why?
|
| Skin Neoplasms | 18 | 2018 | 5812 | 1.610 |
Why?
|
| Melanoma | 17 | 2018 | 5697 | 1.500 |
Why?
|
| Evidence-Based Medicine | 17 | 2020 | 3680 | 1.390 |
Why?
|
| Dermatology | 14 | 2012 | 918 | 1.280 |
Why?
|
| Clindamycin | 2 | 2019 | 139 | 1.260 |
Why?
|
| Rifampin | 3 | 2019 | 339 | 1.190 |
Why?
|
| Dermatologic Agents | 4 | 2019 | 313 | 1.150 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2019 | 177 | 1.130 |
Why?
|
| Warts | 5 | 2005 | 66 | 1.110 |
Why?
|
| Sunscreening Agents | 5 | 2011 | 139 | 0.950 |
Why?
|
| Tinea Versicolor | 2 | 2015 | 9 | 0.870 |
Why?
|
| Skin Diseases | 10 | 2014 | 1094 | 0.760 |
Why?
|
| Medical Records | 5 | 2009 | 1407 | 0.760 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 1269 | 0.740 |
Why?
|
| Lichen Planus | 4 | 2009 | 70 | 0.720 |
Why?
|
| Isotretinoin | 4 | 2019 | 134 | 0.670 |
Why?
|
| Alopecia | 2 | 2020 | 412 | 0.640 |
Why?
|
| Keratosis, Actinic | 1 | 2019 | 72 | 0.630 |
Why?
|
| Platelet-Rich Plasma | 1 | 2020 | 178 | 0.600 |
Why?
|
| Lichen Planus, Oral | 2 | 2012 | 57 | 0.580 |
Why?
|
| Scabies | 2 | 2011 | 14 | 0.550 |
Why?
|
| Drug Eruptions | 7 | 2001 | 335 | 0.540 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2018 | 264 | 0.520 |
Why?
|
| Periodicals as Topic | 5 | 2009 | 1463 | 0.490 |
Why?
|
| Meta-Analysis as Topic | 5 | 2018 | 1380 | 0.450 |
Why?
|
| Bibliometrics | 2 | 2009 | 352 | 0.440 |
Why?
|
| Acne Vulgaris | 1 | 2019 | 349 | 0.440 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 170 | 0.410 |
Why?
|
| Cryotherapy | 5 | 2005 | 159 | 0.400 |
Why?
|
| Standard of Care | 1 | 2015 | 551 | 0.390 |
Why?
|
| Dermatitis, Atopic | 2 | 2011 | 731 | 0.370 |
Why?
|
| Publication Bias | 2 | 2009 | 160 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 7 | 2015 | 7389 | 0.360 |
Why?
|
| Evaluation Studies as Topic | 2 | 2011 | 1623 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 7402 | 0.360 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 2913 | 0.350 |
Why?
|
| Probiotics | 1 | 2013 | 378 | 0.340 |
Why?
|
| Patient Selection | 3 | 2018 | 4237 | 0.340 |
Why?
|
| Dermatitis, Contact | 4 | 1994 | 133 | 0.340 |
Why?
|
| Ultraviolet Rays | 2 | 2011 | 1079 | 0.320 |
Why?
|
| Skin Tests | 1 | 2011 | 637 | 0.320 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 833 | 0.290 |
Why?
|
| Review Literature as Topic | 3 | 2008 | 347 | 0.280 |
Why?
|
| Diarrhea | 1 | 2013 | 1317 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 10199 | 0.270 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 1914 | 0.270 |
Why?
|
| Humans | 88 | 2020 | 760617 | 0.270 |
Why?
|
| Peer Review, Research | 1 | 2009 | 339 | 0.260 |
Why?
|
| Clothing | 2 | 2011 | 96 | 0.250 |
Why?
|
| Antifungal Agents | 2 | 2015 | 753 | 0.240 |
Why?
|
| Immunologic Factors | 1 | 2013 | 1589 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 2164 | 0.230 |
Why?
|
| Langerhans Cells | 4 | 1994 | 170 | 0.230 |
Why?
|
| Griseofulvin | 1 | 2003 | 10 | 0.230 |
Why?
|
| Salicylic Acid | 4 | 2005 | 62 | 0.220 |
Why?
|
| Tinea Capitis | 1 | 2003 | 15 | 0.220 |
Why?
|
| Hybridomas | 4 | 1994 | 442 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 1996 | 346 | 0.210 |
Why?
|
| T-Lymphocytes | 9 | 2000 | 10175 | 0.200 |
Why?
|
| Keratinocytes | 3 | 2002 | 790 | 0.200 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 7995 | 0.190 |
Why?
|
| Publishing | 1 | 2009 | 832 | 0.190 |
Why?
|
| Editorial Policies | 1 | 2006 | 458 | 0.190 |
Why?
|
| Cyclosporine | 1 | 2004 | 778 | 0.190 |
Why?
|
| Monophenol Monooxygenase | 1 | 2001 | 72 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2018 | 23972 | 0.180 |
Why?
|
| Cimetidine | 3 | 2005 | 76 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1921 | 0.180 |
Why?
|
| Permethrin | 1 | 2000 | 15 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2013 | 2279 | 0.170 |
Why?
|
| Safety | 2 | 2003 | 1149 | 0.170 |
Why?
|
| Health Behavior | 1 | 2011 | 2643 | 0.170 |
Why?
|
| Bleomycin | 3 | 2005 | 494 | 0.160 |
Why?
|
| Quackery | 1 | 1998 | 6 | 0.160 |
Why?
|
| Herpes Genitalis | 1 | 2000 | 149 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2009 | 1579 | 0.160 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 191 | 0.160 |
Why?
|
| Eczema | 1 | 2001 | 246 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2001 | 1810 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2020 | 185 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2006 | 1528 | 0.160 |
Why?
|
| Herpes Zoster | 1 | 2001 | 253 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 114 | 0.150 |
Why?
|
| Virus Activation | 1 | 2000 | 320 | 0.150 |
Why?
|
| Insecticides | 1 | 2000 | 191 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11116 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2001 | 733 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 3752 | 0.150 |
Why?
|
| Biochemical Phenomena | 1 | 2017 | 58 | 0.150 |
Why?
|
| Placebo Effect | 1 | 2001 | 518 | 0.150 |
Why?
|
| Nevus, Pigmented | 1 | 1999 | 222 | 0.140 |
Why?
|
| Nephritis, Interstitial | 1 | 2018 | 155 | 0.140 |
Why?
|
| Trinitrobenzenes | 2 | 1994 | 45 | 0.140 |
Why?
|
| Methotrexate | 1 | 2004 | 1716 | 0.140 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 3708 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1999 | 549 | 0.130 |
Why?
|
| Malassezia | 1 | 2015 | 8 | 0.130 |
Why?
|
| Psoriasis | 1 | 2004 | 944 | 0.130 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2010 | 186 | 0.120 |
Why?
|
| Laboratories | 1 | 2019 | 458 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2000 | 1128 | 0.120 |
Why?
|
| Scalp | 1 | 1998 | 389 | 0.120 |
Why?
|
| Survival Rate | 3 | 2018 | 12719 | 0.120 |
Why?
|
| Hypopigmentation | 1 | 2015 | 43 | 0.120 |
Why?
|
| Neuralgia | 1 | 2001 | 611 | 0.120 |
Why?
|
| Cryosurgery | 1 | 2019 | 468 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 1994 | 1434 | 0.120 |
Why?
|
| Aftercare | 1 | 2000 | 913 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1990 | 817 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2000 | 2925 | 0.110 |
Why?
|
| Australia | 1 | 2018 | 1248 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2001 | 943 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2018 | 1415 | 0.110 |
Why?
|
| Mass Screening | 1 | 2010 | 5424 | 0.110 |
Why?
|
| Canada | 1 | 2019 | 2118 | 0.110 |
Why?
|
| Edema | 1 | 1998 | 765 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4570 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2018 | 902 | 0.110 |
Why?
|
| Hyperpigmentation | 1 | 2015 | 116 | 0.110 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1994 | 378 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6305 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 1779 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2018 | 1892 | 0.100 |
Why?
|
| Hand Dermatoses | 2 | 1991 | 62 | 0.100 |
Why?
|
| Administration, Topical | 2 | 2002 | 703 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2017 | 1097 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2002 | 4642 | 0.090 |
Why?
|
| Lymph Nodes | 5 | 2015 | 3461 | 0.090 |
Why?
|
| Haptens | 1 | 1989 | 163 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2005 | 3426 | 0.080 |
Why?
|
| Mohs Surgery | 1 | 2012 | 222 | 0.080 |
Why?
|
| Triglycerides | 1 | 2017 | 2459 | 0.080 |
Why?
|
| Receptors, Lymphocyte Homing | 3 | 1994 | 141 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3514 | 0.080 |
Why?
|
| Calmodulin | 1 | 1990 | 218 | 0.080 |
Why?
|
| General Surgery | 1 | 2000 | 1692 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 4174 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 1994 | 1250 | 0.080 |
Why?
|
| Antigens | 1 | 1994 | 1441 | 0.080 |
Why?
|
| Cell Line, Transformed | 2 | 2000 | 866 | 0.080 |
Why?
|
| Epidermis | 2 | 1989 | 527 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 6520 | 0.080 |
Why?
|
| Risk | 1 | 2000 | 9604 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2000 | 9643 | 0.070 |
Why?
|
| Foot Dermatoses | 1 | 1988 | 47 | 0.070 |
Why?
|
| Cyanosis | 1 | 1988 | 82 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 11106 | 0.070 |
Why?
|
| Cell Movement | 2 | 2000 | 5200 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2005 | 64568 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2009 | 957 | 0.070 |
Why?
|
| Skin | 4 | 1994 | 4473 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8516 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2001 | 12758 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 20074 | 0.070 |
Why?
|
| Occlusive Dressings | 1 | 2005 | 52 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 15828 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 7 | 1994 | 6188 | 0.060 |
Why?
|
| Pyrazolones | 1 | 1985 | 8 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14648 | 0.060 |
Why?
|
| Tretinoin | 1 | 1988 | 519 | 0.060 |
Why?
|
| United States | 6 | 2019 | 72272 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 4845 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2017 | 2015 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 7 | 2000 | 9172 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 22131 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 1018 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2006 | 277 | 0.060 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 1993 | 897 | 0.060 |
Why?
|
| Incidence | 4 | 2010 | 21337 | 0.060 |
Why?
|
| Female | 19 | 2017 | 392148 | 0.050 |
Why?
|
| Counseling | 1 | 2011 | 1538 | 0.050 |
Why?
|
| Epitopes | 1 | 1989 | 2501 | 0.050 |
Why?
|
| Prevalence | 3 | 2009 | 15689 | 0.050 |
Why?
|
| Lymphocyte Activation | 5 | 2002 | 5463 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 157 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2003 | 198 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2000 | 1865 | 0.050 |
Why?
|
| Dendritic Cells | 3 | 1996 | 2722 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 9277 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 678 | 0.050 |
Why?
|
| Iceland | 1 | 2001 | 184 | 0.050 |
Why?
|
| Cell Degranulation | 1 | 2002 | 277 | 0.050 |
Why?
|
| Virus Cultivation | 1 | 2000 | 88 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 3 | 1994 | 963 | 0.040 |
Why?
|
| Toluidines | 1 | 2000 | 21 | 0.040 |
Why?
|
| Male | 14 | 2017 | 360358 | 0.040 |
Why?
|
| Turkey | 1 | 2000 | 253 | 0.040 |
Why?
|
| Ivermectin | 1 | 2000 | 46 | 0.040 |
Why?
|
| Virus Shedding | 1 | 2000 | 109 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2009 | 22148 | 0.040 |
Why?
|
| Life Style | 1 | 2011 | 3904 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1989 | 2270 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2001 | 712 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 4341 | 0.040 |
Why?
|
| Netherlands | 1 | 2004 | 2221 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 1700 | 0.040 |
Why?
|
| MEDLINE | 1 | 1998 | 119 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 2000 | 4172 | 0.040 |
Why?
|
| Dermis | 1 | 2000 | 202 | 0.040 |
Why?
|
| Sunlight | 1 | 2000 | 337 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 1349 | 0.040 |
Why?
|
| Sweden | 1 | 2000 | 1379 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2000 | 870 | 0.040 |
Why?
|
| Time Factors | 1 | 2018 | 39913 | 0.030 |
Why?
|
| Calcium | 1 | 1990 | 5717 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2003 | 1092 | 0.030 |
Why?
|
| Adult | 8 | 2017 | 220969 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2000 | 12966 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2000 | 1336 | 0.030 |
Why?
|
| Research Design | 2 | 2005 | 6174 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 3196 | 0.030 |
Why?
|
| Piroxicam | 2 | 1985 | 18 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 1996 | 445 | 0.030 |
Why?
|
| Thiazines | 2 | 1985 | 38 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13635 | 0.030 |
Why?
|
| Cytoplasm | 2 | 1990 | 1503 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 1994 | 2802 | 0.030 |
Why?
|
| Mast Cells | 1 | 2002 | 1392 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 2017 | 293 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1994 | 222 | 0.030 |
Why?
|
| Cell Line | 3 | 2000 | 15576 | 0.030 |
Why?
|
| Palmitic Acids | 1 | 1994 | 53 | 0.030 |
Why?
|
| Patient Care | 1 | 2000 | 621 | 0.030 |
Why?
|
| Propionates | 2 | 1985 | 183 | 0.030 |
Why?
|
| Mice | 12 | 1996 | 81368 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 80566 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 1996 | 410 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2000 | 1970 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2000 | 3088 | 0.030 |
Why?
|
| Chloroquine | 1 | 1994 | 274 | 0.030 |
Why?
|
| Europe | 1 | 1999 | 3413 | 0.030 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2012 | 25 | 0.030 |
Why?
|
| Formaldehyde | 1 | 1994 | 357 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2002 | 2299 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2000 | 18937 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2008 | 4321 | 0.030 |
Why?
|
| Animals | 13 | 2002 | 168201 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2001 | 2160 | 0.020 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 1985 | 246 | 0.020 |
Why?
|
| Carrier Proteins | 3 | 1994 | 4935 | 0.020 |
Why?
|
| Albumins | 1 | 1994 | 575 | 0.020 |
Why?
|
| Random Allocation | 1 | 1996 | 2392 | 0.020 |
Why?
|
| Risk Factors | 3 | 2011 | 74115 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2000 | 3145 | 0.020 |
Why?
|
| Research | 1 | 2000 | 1977 | 0.020 |
Why?
|
| Leg Ulcer | 1 | 1991 | 71 | 0.020 |
Why?
|
| Demecolcine | 1 | 1990 | 18 | 0.020 |
Why?
|
| Cytochalasin B | 1 | 1990 | 74 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 56 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 1994 | 1887 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1996 | 2604 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1990 | 167 | 0.020 |
Why?
|
| Reference Values | 2 | 1994 | 4919 | 0.020 |
Why?
|
| Multigene Family | 1 | 1993 | 1076 | 0.020 |
Why?
|
| Forecasting | 1 | 1998 | 2924 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 2238 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 799 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2000 | 3998 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 1989 | 1759 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1990 | 352 | 0.020 |
Why?
|
| Acrodermatitis | 1 | 1988 | 15 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 1996 | 9586 | 0.020 |
Why?
|
| Protein Kinase C | 2 | 1990 | 1202 | 0.020 |
Why?
|
| Vagina | 1 | 1993 | 841 | 0.020 |
Why?
|
| Recurrence | 1 | 2000 | 8426 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 1987 | 157 | 0.020 |
Why?
|
| Teratogens | 1 | 1988 | 117 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1991 | 465 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1993 | 1409 | 0.020 |
Why?
|
| Raynaud Disease | 1 | 1988 | 79 | 0.020 |
Why?
|
| Polymers | 1 | 1994 | 1614 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 557 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 791 | 0.020 |
Why?
|
| Middle Aged | 4 | 2009 | 220584 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2001 | 54360 | 0.020 |
Why?
|
| Tubulin | 1 | 1990 | 692 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2000 | 6233 | 0.020 |
Why?
|
| Transcription Factors | 2 | 1996 | 12116 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 1991 | 1083 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 1988 | 188 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9476 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1996 | 2688 | 0.020 |
Why?
|
| Adolescent | 3 | 2017 | 88234 | 0.020 |
Why?
|
| Meclofenamic Acid | 1 | 1984 | 23 | 0.020 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1988 | 339 | 0.020 |
Why?
|
| Tolmetin | 1 | 1984 | 24 | 0.020 |
Why?
|
| Sulindac | 1 | 1984 | 29 | 0.020 |
Why?
|
| Salicylates | 1 | 1985 | 127 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1998 | 5964 | 0.010 |
Why?
|
| Indomethacin | 1 | 1985 | 323 | 0.010 |
Why?
|
| Child | 2 | 2005 | 80079 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1993 | 2546 | 0.010 |
Why?
|
| Intestines | 1 | 1993 | 1909 | 0.010 |
Why?
|
| Photosensitivity Disorders | 1 | 1984 | 80 | 0.010 |
Why?
|
| Thymus Gland | 3 | 1996 | 1243 | 0.010 |
Why?
|
| Ikaros Transcription Factor | 2 | 1996 | 232 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1994 | 5863 | 0.010 |
Why?
|
| Eye | 1 | 1988 | 712 | 0.010 |
Why?
|
| Foot | 1 | 1988 | 575 | 0.010 |
Why?
|
| Acetates | 1 | 1985 | 321 | 0.010 |
Why?
|
| Ibuprofen | 1 | 1985 | 229 | 0.010 |
Why?
|
| Cell Count | 1 | 1987 | 1835 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1987 | 1605 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1994 | 3608 | 0.010 |
Why?
|
| Atrophy | 1 | 1988 | 1631 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1990 | 2915 | 0.010 |
Why?
|
| Actins | 1 | 1990 | 2050 | 0.010 |
Why?
|
| Hand | 1 | 1988 | 902 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 10754 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 2197 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1994 | 3394 | 0.010 |
Why?
|
| Phosphorylation | 2 | 1990 | 8311 | 0.010 |
Why?
|
| Pruritus | 1 | 1985 | 378 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 1987 | 871 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1988 | 1333 | 0.010 |
Why?
|
| Hyaluronic Acid | 2 | 1994 | 483 | 0.010 |
Why?
|
| Spleen | 2 | 1996 | 2286 | 0.010 |
Why?
|
| Piperazines | 1 | 1990 | 2521 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1985 | 2358 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2000 | 39063 | 0.010 |
Why?
|
| Bone Marrow Cells | 2 | 1996 | 2409 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1984 | 757 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 4020 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1984 | 917 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 17629 | 0.010 |
Why?
|
| Pyrazoles | 1 | 1985 | 2008 | 0.010 |
Why?
|
| Signal Transduction | 2 | 1994 | 23416 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1996 | 1748 | 0.010 |
Why?
|
| Mitogens | 1 | 1993 | 229 | 0.010 |
Why?
|
| Aspirin | 1 | 1985 | 3127 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1994 | 149 | 0.010 |
Why?
|
| Hospitals | 1 | 1986 | 3877 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1994 | 813 | 0.010 |
Why?
|
| Clone Cells | 1 | 1996 | 1657 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1996 | 684 | 0.010 |
Why?
|
| Base Sequence | 2 | 1994 | 12421 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1490 | 0.010 |
Why?
|
| Mutation | 1 | 1996 | 30016 | 0.010 |
Why?
|
| Cell Differentiation | 3 | 1996 | 11514 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 704 | 0.010 |
Why?
|
| Aged | 3 | 2017 | 169042 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1994 | 837 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 2381 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1991 | 531 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1994 | 2010 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1993 | 1755 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 2100 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 2625 | 0.000 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1996 | 1798 | 0.000 |
Why?
|
| Cell Fusion | 1 | 1989 | 294 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1994 | 3074 | 0.000 |
Why?
|
| Cell Division | 1 | 1994 | 4457 | 0.000 |
Why?
|
| Necrosis | 1 | 1991 | 1610 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1996 | 2909 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 6126 | 0.000 |
Why?
|
| Germ-Line Mutation | 1 | 1994 | 1852 | 0.000 |
Why?
|
| Pregnancy | 1 | 1988 | 29868 | 0.000 |
Why?
|
| Fluorescent Dyes | 1 | 1994 | 1901 | 0.000 |
Why?
|
| Transfection | 1 | 1993 | 5766 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1994 | 2191 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6074 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 4910 | 0.000 |
Why?
|
| RNA | 1 | 1993 | 2713 | 0.000 |
Why?
|
| Protein Binding | 1 | 1994 | 9345 | 0.000 |
Why?
|
| Mice, Transgenic | 1 | 1994 | 9529 | 0.000 |
Why?
|
| Liver | 1 | 1996 | 7512 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 7196 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1989 | 13441 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 1994 | 22115 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1987 | 11874 | 0.000 |
Why?
|